Dulaglutide vs Tesofensine
Head-to-head comparison of Dulaglutide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Dulaglutide | Tesofensine |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Weight Loss / Reuptake Inhibitor |
| Mechanism | Dulaglutide is a GLP-1 receptor agonist consisting of two identical disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence (90% homology to native GLP-1) fused to a modified human IgG4 Fc fragment via a small peptide linker. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | A — FDA Approved | C — Phase II–III Clinical Trials |
| Clinical Status | FDA-approved (Trulicity for T2D, September 2014; cardiovascular risk reduction, 2020) | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Common (>=5%): nausea (12-21%), diarrhea (8-13%), vomiting (6-12%), abdominal pain, decreased appetite; GI side effects are dose-dependent and typically transient, decreasing after the first 2-4 weeks | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~59,670 g/mol (fusion protein) | ~397.5 g/mol |
| Half-Life | ~5 days (approximately 120 hours) | N/A |
Overview
Dulaglutide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Dulaglutide — Mechanism & Evidence
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. It is a fusion protein consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a small peptide linker (MW ~59,670 g/mol). The Fc fusion extends its half-life to approximately 5 days, enabling once-weekly dosing. Dulaglutide is administered via a single-dose pen device that does not require reconstitution.
Key claims: Effective glycemic control in type 2 diabetes; Produces clinically meaningful weight loss; Reduces major adverse cardiovascular events.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Dulaglutide focuses on Metabolic Health, Cardiovascular, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Dulaglutide: Common (>=5%): nausea (12-21%), diarrhea (8-13%), vomiting (6-12%), abdominal pain, decreased appetite GI side effects are dose-dependent and typically transient, decreasing after the first 2-4 weeks Hypoglycemia risk increased when combined with insulin or sulfonylureas
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.